---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-044934"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-11-19T22:00:02+00:00"
generated_at: "2026-11-19T22:02:13.182480+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools holders approve Treeline merger, reverse split up to 1-for-40, Mass Cytometry sale

## Summary
- All seven special-meeting proposals passed; share issuance for the Treeline Biosciences merger won 274,099,041 votes for vs 7,571,806 against.
- Charter amendment approved to effect a reverse split of 1-for-20 to 1-for-40, ratio to be mutually agreed with Treeline, and rename the company Treeline Biosciences, Inc.
- Element Mass Cytometry divestiture to Element Biosystems, LLC (a GMT Venture Partners vehicle) approved 276,299,544 to 5,336,020.
- Quorum of 281,744,412 votes, about 71.38% of the 394,711,296 shares outstanding as of the October 16, 2026 record date; no broker non-votes.
- Treeline merger expected to close in Q4 2026, with the Mass Cytometry sale closing substantially concurrently; CEO Michael Egholm called the votes an important step.

## SEC filing metadata
- accession: 0001140361-26-044934
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-11-19T22:00:02+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000114036126044934/0001140361-26-044934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000114036126044934/ef20085888_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-044934
- JSON: https://secwatch.observer/filing/0001140361-26-044934.json
- Plain text: https://secwatch.observer/filing/0001140361-26-044934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
